AR012702A1 - Combinacion de (-)-(1s,4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]- 2-ciclopenteno-1-metanol y un inhibidor dee transcriptasa reversa no nucleosidouna formulacion farmaceutica que comprende la combinacion, su uso medico en terapia para tratar la infeccion de vih, y un empaque para el paciente - Google Patents

Combinacion de (-)-(1s,4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]- 2-ciclopenteno-1-metanol y un inhibidor dee transcriptasa reversa no nucleosidouna formulacion farmaceutica que comprende la combinacion, su uso medico en terapia para tratar la infeccion de vih, y un empaque para el paciente

Info

Publication number
AR012702A1
AR012702A1 ARP980102250A ARP980102250A AR012702A1 AR 012702 A1 AR012702 A1 AR 012702A1 AR P980102250 A ARP980102250 A AR P980102250A AR P980102250 A ARP980102250 A AR P980102250A AR 012702 A1 AR012702 A1 AR 012702A1
Authority
AR
Argentina
Prior art keywords
combination
purin
methanol
amino
patient
Prior art date
Application number
ARP980102250A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9709945.1A external-priority patent/GB9709945D0/en
Priority claimed from GBGB9719883.2A external-priority patent/GB9719883D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR012702A1 publication Critical patent/AR012702A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen combinaciones terapéuticas de (-)(1S,4R)-4-[2-amino-6- (ciclopropilamino)-9H-purin-9-il]-2-ciclopenteno-1-metanol (1592U89) einhibidores de transcriptasa reversa, no nucleosidos que tienen actividad anti- VIH. La presente invencion también está relacionada con composicionesfarmacéuticas que contienen las combinaciones, su uso en el tratamiento de infecciones VIH y un empaque para el paciente que contiene dichas combinaciones
ARP980102250A 1997-05-17 1998-05-14 Combinacion de (-)-(1s,4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]- 2-ciclopenteno-1-metanol y un inhibidor dee transcriptasa reversa no nucleosidouna formulacion farmaceutica que comprende la combinacion, su uso medico en terapia para tratar la infeccion de vih, y un empaque para el paciente AR012702A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9709945.1A GB9709945D0 (en) 1997-05-17 1997-05-17 A novel salt
GBGB9719883.2A GB9719883D0 (en) 1997-09-19 1997-09-19 Antiviral combinations

Publications (1)

Publication Number Publication Date
AR012702A1 true AR012702A1 (es) 2000-11-08

Family

ID=26311543

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102250A AR012702A1 (es) 1997-05-17 1998-05-14 Combinacion de (-)-(1s,4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]- 2-ciclopenteno-1-metanol y un inhibidor dee transcriptasa reversa no nucleosidouna formulacion farmaceutica que comprende la combinacion, su uso medico en terapia para tratar la infeccion de vih, y un empaque para el paciente

Country Status (12)

Country Link
EP (1) EP0979082A1 (es)
JP (1) JP2001525839A (es)
AR (1) AR012702A1 (es)
AU (1) AU7912398A (es)
BR (1) BR9809127A (es)
CA (1) CA2289655A1 (es)
CO (1) CO4950569A1 (es)
HR (1) HRP980264A2 (es)
MA (1) MA26496A1 (es)
NO (1) NO995620L (es)
PE (1) PE74799A1 (es)
WO (1) WO1998052570A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP990030A2 (en) * 1998-02-17 1999-10-31 Michael B. Maurin Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
EP1332757B1 (en) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
PE20000559A1 (es) * 1998-05-27 2000-07-05 Merck & Co Inc Formulacion de tabletas comprimidas de efavirenz
WO2013111147A1 (en) * 2011-12-19 2013-08-01 Hetero Research Foundation Extended release compositions of nevirapine
JP6391561B2 (ja) * 2013-02-27 2018-09-19 国立大学法人京都大学 がんの予防または治療用医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc

Also Published As

Publication number Publication date
MA26496A1 (fr) 2004-12-20
AU7912398A (en) 1998-12-11
CA2289655A1 (en) 1998-11-26
HRP980264A2 (en) 1999-02-28
JP2001525839A (ja) 2001-12-11
NO995620D0 (no) 1999-11-16
WO1998052570A1 (en) 1998-11-26
BR9809127A (pt) 2000-08-01
EP0979082A1 (en) 2000-02-16
CO4950569A1 (es) 2000-09-01
PE74799A1 (es) 1999-08-13
NO995620L (no) 2000-01-14

Similar Documents

Publication Publication Date Title
AR020055A1 (es) Una composicion farmaceutica o cosmetica que contiene una sustancia de esmalte activa, usos de dicha composicion y un metodo para preparar la misma.
PT88985A (pt) Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina
ES2145913T3 (es) Inhibidores de metaloproteasas.
HUP0104718A2 (hu) Mikronizált eplerenon kompozíciók és eljárás az előállításukra
RU94026283A (ru) Фармацевтическое соединение
RU2007104774A (ru) Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы
AR003440A1 (es) Nuevos derivados de aminoacidos, formulacion farmaceutica que los contiene, uso de dichos derivados para preparar medicamentos y procedimiento para la preparacion de dichos derivados.
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
AR012294A1 (es) Derivados de sulfonamida, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen, uso de dichos derivados para lapreparacion de un medicamento.
PT914110E (pt) Metodo de modulacao da micro-circulacao
AR031117A1 (es) Uso de inhibidores de lipasa y secuestrantes de acido biliar para la preparacion de un medicamento, dicho inhibidor de lipasa y secuestrante de acido biliar y combinacion farmaceutica
DE69718734D1 (de) Bicyclische aromatische verbindungen
HUP0100539A2 (hu) D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására
HUP0001632A2 (hu) Szelektív foszfodiészteráz PDE enzim inhibitort tartalmazó gyógyszerkészítmények
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
AR012702A1 (es) Combinacion de (-)-(1s,4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]- 2-ciclopenteno-1-metanol y un inhibidor dee transcriptasa reversa no nucleosidouna formulacion farmaceutica que comprende la combinacion, su uso medico en terapia para tratar la infeccion de vih, y un empaque para el paciente
MXPA03010679A (es) Una composicion para acelerar la cicatrizacion de fractura osea.
ATE395064T1 (de) Kombinationspräparate von 3-n- formylhydroxylaminopropylphosphonsäurederivaten oder 3-n- acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
BR0206954A (pt) Processo de terapia para câncer
UY26595A1 (es) Formulaciones de entecavir de dosis bajas y uso
RU2005131578A (ru) Аплидин для лечения множественной миеломы
AR002957A1 (es) Una combinacion de compuestos utiles, su uso para preparar un medicamento, y una composicion y combinacion farmaceutica que los contienen.
AR036009A1 (es) Composicion farmaceutica para el tratamiento o prevencion del dolor visceral y los trastornos gastrointestinales que comprenden un compuesto aminoácido biciclico y uso de este ultimo para fabricar dicha composicion farmaceutica
BR9809124A (pt) Combinação, formulação, farmacêutica, processo para o tratamento de uma infecção por hiv em um animal, infectado, uso de (-)-(1s, 4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-cicl openteno-1-metanol, e, pacote de paciente
HUP0204180A2 (hu) Külsőleges készítmény és alkalmazása allergiás dermatitisz kezelésére